Diagnosis and new treatments in muscular dystrophies

Postgraduate Medical Journal

Volumn 85, Issue 1009, 2009, Pages 622-630

  Manzur, A Y ^a   Muntoni, F ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SARCOGLYCAN; ANTISENSE OLIGONUCLEOTIDE; ATALUREN; AVI 4658; CALPAIN; CAVEOLIN 3; CONNECTIN; DEFLAZACORT; DYSFERLIN; DYSTROPHIN; FUKUTIN RELATED PROTEIN; GENTAMICIN; LAMIN; LAMIN AC; PERINDOPRIL; PLACEBO; PREDNISONE; UNCLASSIFIED DRUG;

BECKER MUSCULAR DYSTROPHY; CLINICAL TRIAL; CODON; CONGESTIVE CARDIOMYOPATHY; DIETARY INTAKE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; ELECTROMYOGRAM; EXON; GENE MUTATION; HEART LEFT VENTRICLE FAILURE; HETEROZYGOTE; HUMAN; HYPOXEMIA; LIMB GIRDLE MUSCULAR DYSTROPHY; LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 1B; LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 1C; LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2A; LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2B; LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2D; LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2I; LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2J; MIYOSHI MYOPATHY; MOTOR DYSFUNCTION; NONHUMAN; OPTIMAL DRUG DOSE; ORTHOSIS; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOTHERAPY; REVIEW; RNA INTERFERENCE; SCOLIOSIS; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP DISORDERED BREATHING; SPINE SURGERY; SURVIVAL; VERTEBRA FRACTURE; WEIGHT GAIN;

EID: 73349127499     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/jnnp.2008.158329     Document Type: Review

References (81)

1. Emery AE, Muntoni F. Duchenne muscular dystrophy. Oxford: Oxford University Press, 2003.
2. Essex C, Roper H. Lesson of the week: late diagnosis of Duchenne's muscular dystrophy presenting as global developmental delay. BMJ 2001;323:37-8.
3. Manzur AY, Kinali M, Muntoni F. Update on the management of Duchenne muscular dystrophy. Arch Dis Child 2008;93:986-90.
4. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003;2:731-40.
5. Chamberlain JS, Gibbs RA, Ranier JE, et al. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res 1988;16:11141-56.
6. Schwartz M, Duno M. Improved molecular diagnosis of dystrophin gene mutations using the multiplex ligation-dependent probe amplification method. Genet Test 2004;8:361-7.
7. Ashton EJ, Yau SC, Deans ZC, et al. Simultaneous mutation scanning for gross deletions, duplications and point mutations in the DMD gene. Eur J Hum Genet 2008;16:53-61.
8. Dubowitz V, Sewry CA. Muscle biopsy. A practical approach. Saunders Elsevier 2007.
9. Eagle M. Report on the muscular dystrophy campaign workshop: exercise in neuromuscular diseases Newcastle, January 2002. Neuromuscul Disord 2002;12:975-83.
10. Rodillo EB, Fernandez-Bermejo E, Heckmatt JZ, et al. Prevention of rapidly progressive scoliosis in Duchenne muscular dystrophy by prolongation of walking with orthoses. J Child Neurol 1988;3:269-74.
11. Manzur AY, Kuntzer T, Pike M, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008;(1):CD003725.
12. Biggar WD, Harris VA, Eliasoph L, et al. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249-55.
13. King WM, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007;68:1607-13.
14. Beenakker EA, et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch Neurol 2005;62:128-32.
15. Bushby K, Muntoni F, Urtizberea A, et al. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromuscul Disord 2004;14:526-34.
16. Quinlivan R, et al. Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. Neuromuscul Disord 2005;15:72-9.
17. Smith PE, Calverley PM, Edwards RH. Hypoxemia during sleep in Duchenne muscular dystrophy. Am Rev Respir Dis 1988;137:884-8.
18. Simonds AK, Muntoni F, Heather S, et al. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax 1998;53:949-52.
19. Eagle M, et al. Managing Duchenne muscular dystrophy-the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 2007;17:470-5.
20. Hill NS. Noninvasive positive pressure ventilation in neuromuscular disease. Enough is enough! Chest 1994;105:337-8.
21. Toussaint M, Steens M, Soudon P. Lung function accurately predicts hypercapnia in patients with Duchenne muscular dystrophy. Chest 2007;131:368-75.
22. Ward S, Chatwin M, Heather S, et al. Randomised controlled trial of non-invasive ventilation (NIV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia. Thorax 2005;60:1019-24.
23. English KM, Gibbs JL. Cardiac monitoring and treatment for children and adolescents with neuromuscular disorders. Dev Med Child Neurol 2006;48:231-5.
24. Duboc D, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007;154:596-602.
25. Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, The Netherlands. Neuromuscul Disord 2003;13:166-72.
26. Muntoni F, Bushby K, Manzur AY. Muscular Dystrophy Campaign Funded Workshop on Management of Scoliosis in Duchenne Muscular Dystrophy, 24 January 2005. London: Neuromuscul Disord 2006;16:210-19.
27. Marsh A, Edge G, Lehovsky J. Spinal fusion in patients with Duchenne's muscular dystrophy and a low forced vital capacity. Eur Spine J 2003;12:507-12.
28. Pane M, et al. Feeding problems and weight gain in Duchenne muscular dystrophy. Eur J Paediatr Neurol 2006;10:231-6.
29. Kohler M, Clarenbach CF, Bahler C, et al. Disability and survival in Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2009;80:320-25.
30. Maha JK, Thannhauser JE, McNeilBeing DA, et al. The lifeline: The parent experience of caring for a child with neuromuscular disease on home mechanical ventilation. Neuromuscul Disord 2008;18:983-8.
31. Parker AE, et al. Analysis of an adult Duchenne muscular dystrophy population. QJM 2005;98:729-36.
32. Shumyatcher Y, Shah TA, Noritz GA, et al. Symptomatic nephrolithiasis in prolonged survivors of Duchenne muscular dystrophy. Neuromuscul Disord 2008;18:561-4.
33. Wells DJ. Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy. J Muscle Res Cell Motil 2006;27:387- 98.
34. Alter J, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006;12:175-7.
35. van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. New Engl J Med 2007;357:2677-86.
36. Wilton S. PTC124, nonsense mutations and Duchenne muscular dystrophy. Neuromuscul Disord 2007;17:719-20.
37. Barton-Davis ER, Cordier L, Shoturma DI, et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999;104:375-81.
38. Wagner KR, Hamed S, Hadley DW, et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001;49:706-11.
39. Hirawat S, Welch EM, Elfring GL, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007;47:430-44.
40. Emery AEH. Population frequencies of inherited neuromuscular diseases: a world survey. Neuromuscul Disord 1991;1:19-29.
41. Melacini P, Fanin M, Danieli GA, et al. Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. Circulation 1996;94:3168-75.
42. Shoji1 T, Nishikawa Y2, Saito1 N, et al. A case of Becker muscular dystrophy and massive myoglobinuria with minimal renal manifestations. Nephrol Dial Transplant 1998;13:759-60.
43. Hayes J, Veckemans F, Bissonette B. Duchenne muscular dystrophy: an old anesthesia problem revisited. Pediatric Anesthesia 2008;18:100-6.
44. Kesari A, Pirra LN, Bremadesam L, et al. Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule. Hum Mutat 2008;29:728-37.
45. Young KH, Barton BA, Waisbren S, et al. Cognitive and psychological profile of males with Becker muscular dystrophy. J Child Neurol 2008;23:155.
46. Hoogerwaard EM, Bakker E, Ippel PF, et al. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet 1999 19;353:2116-19.
47. Hoogerwaard EM, Ginjaar IB, Bakker E, et al. Dystrophin analysis in carriers of Duchenne and Becker muscular dystrophy. Neurology 2005;65:1984-6.
48. Dubowitz V. What's in a name? Muscular dystrophy revisited. Eur J Paediatr Neurol 1998;2:279-84.
49. Laval SH, Bushby KM. Limb-girdle muscular dystrophies-from genetics to molecular pathology. Neuropathol Appl Neurobiol 2004;30:91-105.
50. Kanagawa M, Toda T. The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis. J Hum Genet 2006;51:915-26.
51. Guglieri M, Straub V, Bushby K, et al. Limb-girdle muscular dystrophies. Curr Opin Neurol 2008;21:576-84.
52. Norwood F, de Visser M, Eymard B, et al. EFNS Guideline Task Force. EFNS guideline on diagnosis and management of limb girdle muscular dystrophies. Eur J Neurol 2007;14:1305-12.
53. Guglieri M, Bushby K. How to go about diagnosing and managing the limb-girdle muscular dystrophies. Neurol India 2008;56:271-80.
54. Lo HP, Cooper ST, Evesson FJ, et al. Limb-girdle muscular dystrophy: diagnostic evaluation, frequency and clues to pathogenesis. Neuromuscul Disord 2008;18:34-44.
55. Bonne G, Mercuri E, Muchir A, et al. Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. Ann Neurol 2000;48:170-80.
56. Mercuri E, Pichiecchio A, Allsop J, et al. Muscle MRI in inherited neuromuscular disorders: past, present, and future. J Magn Reson Imaging 2007;25:433-40.
57. Figarella-Branger D, El-Dassouki M, Saenz A. Myopathy with lobulated muscle fibers: evidence for heterogeneous etiology and clinical presentation. Neuromuscul Disord 2002;12:4-12.
58. Quijano-Roy S, Mbieleu B, Bönnemann CG, et al. De Novo LMNA mutations cause a new form of congenital muscular dystrophy. Ann Neurol 2008;64:177-86.
59. Aboumousa A, Hoogendijk J, Charlton R. Caveolinopathy-new mutations and additional symptoms. Neuromuscul Disord 2008;18:572-8.
60. Beckmann JS, Spencer M. Calpain 3, the "gatekeeper" of proper sarcomere assembly, turnover and maintenance. Neuromuscul Disord 2008;18:913-21.
61. Mercuri E, Bushby K, Ricci E, et al. Muscle MRI findings in patients with limb girdle muscular dystrophy with calpain 3 deficiency (LGMD2A) and early contractures. Neuromuscul Disord 2005;15:164-71.
62. Piluso G, Politano L, Aurino S, et al. Extensive scanning of the calpain-3 gene broadens the spectrum of LGMD2A phenotypes. J Med Genet 2005;42:686-93.
63. Milic A, Daniele N, Lochmüller H, et al. A third of LGMD2A biopsies have normal calpain 3 proteolytic activity as determined by an in vitro assay. Neuromuscul Disord 2007;17:148-56.
64. Nguyen K, Bassez G, Krahn M. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 2007;64:1176-82.
65. Krahn M, Béroud C, Labelle V. Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat 2008 Oct 13.
66. Eymard B, Romero NB, Leturcq F, et al. Primary adhalinopathy (alphasarcoglycanopathy): Clinical, pathologic, and genetic correlation in 20 patients with autosomal recessive muscular dystrophy. Neurology 1997;48:1227-34.
67. Schara U, Gencik M, Mortier J. Alpha-sarcoglycanopathy previously misdiagnosed as Duchenne muscular dystrophy: implications for current diagnostics and patient care. Eur J Pediatr 2001;160:452-3.
68. Klinge L, Dekomien G, Aboumousa A. Sarcoglycanopathies: Can muscle immunoanalysis predict the genotype? Neuromuscul Disord 2008;18:934-41.
69. Rodino-Klapac LR, Lee JS, Mulligan RC, et al. Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D. Neurology 2008;71:240-7.
70. Poppe M, Cree L, Bourke J. The phenotype of limb-girdle muscular dystrophy type 2I. Neurology 2003;60:1246-51.
71. Griggs RC, Bushby K. Continued need for caution in the diagnosis of Duchenne muscular dystrophy. Neurology 2005;64:1498-9.
72. Gaul C, Deschauer M, Tempelmann C. Cardiac involvement in limb-girdle muscular dystrophy 2I: conventional cardiac diagnostic and cardiovascular magnetic resonance. Neurol 2006;253:1317-22.
73. Muntoni F, Brockington M, Godfrey C. Muscular dystrophies due to defective glycosylation of dystroglycan. Acta Myol 2007;26:129-35.
74. Balci B, Uyanik G, Dincer P. An autosomal recessive limb girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic to Walker-Warburg syndrome (WWS) caused by a mutation in the POMT1 gene. Neuromuscul Disord 2005;15:271-5.
75. Clement EM, Godfrey C, Tan J. Mild POMGnT1 mutations underlie a novel limbgirdle muscular dystrophy variant. Arch Neurol 2008;65:137-41.
76. Darin N, Kroksmark AK, Ahlander AC. Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2I. Eur J Paediatr Neurol 2007;11:353-7.
77. Godfrey C, Escolar D, Brockington M. Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy. Ann Neurol 2006;60:603-10.
78. Muntoni F, Torelli S, Brockington M. Muscular dystrophies due to glycosylation defects. Neurotherapeutics 2008;5:627-32.
79. Udd B, Partanen J, Halonen P, et al. Tibial muscular dystrophy-late adult-onset distal myopathy in 66 Finnish patients. Arch Neurol 1993;50:604-8.
80. Udd B, Vihola A, Sarparanta J, et al. Titinopathies and extension of the M-line mutation phenotype beyond distal myopathy and LGMD2J. Neurology 2005;64:636-42.
81. Carmignac V, Salih MAM, Quijano-RoyS, et al. C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy. Ann Neurol 2007;61:340-51.